Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 6/20 | 0.52 |
| ▸ | PDE4A | P27815 | 6/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.48 |
| ▸ | DPP4 | P27487 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235849 | 0.96 | MAPK8 (0.50) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5576568 | 0.91 | DPP4 (0.48) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5235815 | 0.90 | NMT1 (0.49) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5240152 | 0.89 | DPP4 (0.44) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27599395 | 0.87 | DPP4 (0.48) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5238135 | 0.86 | NMT1 (0.47) | DPP4LMNAALDH1A1MAOB | |
| SCHEMBL5236803 | 0.85 | DPP4 (0.44) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5238527 | 0.83 | MAPK8 (0.60) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5236435 | 0.82 | MAPK8 (0.58) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5232010 | 0.82 | MAPK8 (0.61) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| CN-1500080-A | Fused heterocyclic compounds | ����ҩƷ��ҵ��ʽ���� | 2004-05-26 | — | — | CN | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | PDE5A 3104/4885PDE4A 3552/4885PDE4B 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.